Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intra-arterial Chemotherapy Clear all
Completed Not applicable Interventional

A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma

NCT00857519
View directory record Official record
Conditions
Retinoblastoma
Interventions
Melphalan, Carboplatin
Drug
Lead sponsor
Wills Eye
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 17, 2026, 3:35 AM EDT
Withdrawn Phase 2 Interventional

Chemo-embolization for Head and Neck Cancer

NCT04595981
View directory record Official record
Conditions
SCCHN, Squamous Cell Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 3:35 AM EDT
Not listed Not applicable Interventional

TReatment Of Pulmonary HYpertension 1-US Study

NCT02835950
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Therapeutic Intra-Vascular UltraSound (TIVUS™) System
Device
Lead sponsor
SoniVie Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
San Diego, California • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 1Phase 2 Interventional

Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma

NCT00901238
View directory record Official record
Conditions
Retinoblastoma
Interventions
Intra-arterial Chemotherapy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Month and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

NCT02819479
View directory record Official record
Conditions
Radiation Necrosis
Interventions
25% Mannitol, Low-dose Intra-arterial Bevacizumab
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 17, 2026, 3:35 AM EDT
Withdrawn Phase 2 Interventional

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

NCT02850874
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Adenocarcinoma
Interventions
Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 17, 2026, 3:35 AM EDT
Recruiting Phase 2 Interventional

Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment

NCT07361549
View directory record Official record
Conditions
Refractory Migraine, Headache
Interventions
Lidocaine (drug), Saline
Drug
Lead sponsor
Daniel A Tonetti, MD
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma

NCT00183885
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
mitomycin-c, cisplatin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 17, 2026, 3:35 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

NCT00075387
View directory record Official record
Conditions
Malignant Glioma
Interventions
Carboplatin, Cyclophosphamide, Etoposide Phosphate, Quality-of-Life Assessment, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
3
States / cities
Minneapolis, Minnesota • Cleveland, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 1 Interventional

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

NCT00972036
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
SIR-spheres® (Selective Internal Radiation Therapy)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 17, 2026, 3:35 AM EDT
Terminated Phase 1 Interventional

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

NCT02116959
View directory record Official record
Conditions
Advanced Intra-Ocular Retinoblastoma, Retinoblastoma
Interventions
Melphalan, Carboplatin, Etoposide, Vincristine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 17, 2026, 3:35 AM EDT
Enrolling by invitation No phase listed Observational

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

NCT03662776
View directory record Official record
Conditions
Survivors of Unilateral Retinoblastoma
Interventions
BASC-3 survey, PROMIS survey
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
8 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 1 Interventional

Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke

NCT02235558
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil
Drug
Lead sponsor
Justin Fraser
Other
Eligibility
21 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 17, 2026, 3:35 AM EDT
Recruiting No phase listed Observational

PumaRx Registry Trial

NCT06805461
View directory record Official record
Conditions
Solid Tumors
Interventions
RenovoCath®
Device
Lead sponsor
RenovoRx
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Coral Gables, Florida • Pittsburgh, Pennsylvania • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 3:35 AM EDT
Withdrawn Phase 2 Interventional

Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma

NCT01151748
View directory record Official record
Conditions
Retinoblastoma, Eye Cancer
Interventions
Intra-arterial infusion of chemotherapy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 17, 2026, 3:35 AM EDT
Terminated Phase 2 Interventional Results available

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

NCT01293539
View directory record Official record
Conditions
Retinoblastoma
Interventions
Melphalan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 17, 2026, 3:35 AM EDT
Completed No phase listed Observational

Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children

NCT03866460
View directory record Official record
Conditions
Intraocular Retinoblastoma, Hearing Loss
Interventions
Distortion product otoacoustic emission measurement (DPOAE)
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Months to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 1 Interventional Results available

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

NCT02097134
View directory record Official record
Conditions
Unilateral Retinoblastoma
Interventions
Melphalan
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Durvalumab, SNDX-6352
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 17, 2026, 3:35 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 17, 2026, 3:35 AM EDT
Terminated Not applicable Interventional Results available

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

NCT00673179
View directory record Official record
Conditions
Osteosarcoma
Interventions
Doxorubicin, Cisplatin, Methotrexate, Leucovorin, Dexrazoxane, Ifosfamide, Questionnaire, Gemcitabine, Sargramostim, Surgery, Mesna
Drug · Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
5 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 17, 2026, 3:35 AM EDT
Completed Phase 1 Interventional

Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).

NCT01688401
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions
Melphalan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Month to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 17, 2026, 3:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer

NCT00816777
View directory record Official record
Conditions
Unresectable Metastatic Colo-rectal Cancer
Interventions
Chemoembolization with irinotecan Bead, Irinotecan
Procedure · Drug
Lead sponsor
Generic Devices Consulting, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 17, 2026, 3:35 AM EDT